 has awarded it two projects with combined revenue of more than $18 million over a three year period of time. The projects are both fixed-dose combination drugs in development for the treatment of the growing population of Type II diabetics. 

In commenting on the announcement, Mark Kontny, Patheon's President of Pharmaceutical Development Services and Chief Scientific Officer said, "I am very gratified that Boehringer Ingelheim recognizes our knowledge in formulating, scaling, and successfully launching complex formulations such as these molecules.  It is this kind of support and recognition that has enabled us to develop our position in pharmaceutical development services."